Aug 2026· Journal of Clinical and Experimental Hematopathology· Vol 66, pp. 238-243· 1 citation· 15 references
Medicine
TL;DR
The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.
Abstract
Although the use of bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is expanding, reports of pseudoprogression following this therapy are scarce. A 58-year-old, male patient with DLBCL achieved a complete response (CR) after fourth-line therapy with lisocabtagene maraleucel. However, 26 months post-infusion, he experienced the development of pelvic lymphadenopathy, which was histologically confirmed as a relapse. Because the disease was refractory to radiotherapy and chemotherapy, epcoritamab was administered as the seventh-line treatment. A fever developing after the second step-up dose (Cycle 1, day 12) was diagnosed as grade 1 cytokine release syndrome and was treated with acetaminophen. Nonetheless, the fever was still present on day 14, when abdominal pain requiring opioid administration also developed. Computed tomography (CT) revealed enlargement of the pelvic lesions and increased ascites. Cytology of the ascites revealed no lymphoma cells and showed a predominantly inflammatory cell composition, while lactate dehydrogenase levels decreased, supporting the diagnosis of pseudoprogression. The treatment was continued and his symptoms gradually improved. After three cycles, positron emission tomography-CT confirmed the complete metabolic response (CMR), which was maintained through nine cycles. The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.
A 55-year-old male, former smoker, presented with exertional dyspnea associated with an anterior mediastinal mass. Biopsy findings were consistent with a type B2 thymoma. The tumor was deemed unresectable, and curative concurrent chemoradiotherapy was not feasible after three cycles of cyclophosphamide, adriamycin (dox...
Amine Benslimane, Layla Mohib, Soumaya El Yakoubi et al.· Cureus· 0 citations
This case highlights the importance of considering AA in the differential diagnosis of persistent thrombocytopenia or pancytopenia during immune checkpoint inhibitor therapy, and reports of AA induced by durvalumab are extremely limited.
K. Maeshima, Yoshiko Sakayori, Hiroki Yokoyama et al.· [Rinsho ketsueki] The Japane...· 0 citations
Richter transformation (RT) that relapses after CD19-directed chimeric antigen receptor (CAR) T-cell therapy has no established therapy and carries a dismal prognosis. We report an 84-year-old man with multiply relapsed, biopsy-proven diffuse large B-cell lymphoma-type RT and a high-risk MYC/BCL2 double-expressor pheno...
Primary thyroid diffuse large B-cell lymphoma (DLBCL) is a rare subset of primary extranodal DLBCL. Thus, there are limited evidence-based specific recommendations regarding its diagnosis and treatment. We present a case report of a patient with relapsed primary thyroid DLBCL, followed by a focused literature review co...
K. Kirkgöz, K. Weisel, Carsten Bokemeyer et al.· Annals of Hematology· 0 citations
This case represents a catastrophic transition of genetically high-risk MM from initial medullary involvement to widespread multivisceral and cardiovascular infiltration upon relapse and highlights a rare phenotype of relapsed/refractory MM where aggressive extramedullary proliferation occurs independently of bone marr...
Yu-Hui Wei, Xue-Jiao Yang, Yu-Lan Zheng et al.· Therapeutic Advances in Hema...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.